Statistical models for low dose exposure

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 405, Issue 2, 1998, Pages 227-236

  Edler, Lutz ^a   Kopp Schneider, Annette ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Benchmark risk; Dose response model; Low dose linear; Risk assessment; Stochastic modeling; Threshold

Indexed keywords

CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; DOSE RESPONSE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL MODEL;

AGE FACTORS; ANIMALS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL EXPOSURE; HUMANS; MAXIMUM ALLOWABLE CONCENTRATION; MODELS, STATISTICAL; NEOPLASMS; RISK ASSESSMENT;

EID: 0032552567     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00140-7     Document Type: Conference Paper

References (28)

1. [1] M.A. Schneiderman, P. Decoufle, C.C. Brown, Thresholds for environmental cancer: Biologic and statistical considerations, Ann. NY Acad. Sci. 329 (1979) 92-130.
2. [2] K.S. Crump, D. Hoel, C. Langley, R. Peto, Fundamental carcinogenic processes and their implications for low dose risk assessment, Cancer 36 (1979) 2973-2979.
3. [3] Environmental Protection Agency, Proposed Guidelines for Carcinogenic Risk Assessment; Notice - Part II, Federal Register 61, No. 79, Tuesday April 23, 1996.
4. [4] B.J.T. Morgan, Analysis of Quantal Response Data, Chapman and Hall, London, 1992.
5. [5] N. Mantel, W. Bryan, 'Safety' testing of carcinogenic agents, Journal Natl. Cancer Inst. 27 (1961) 455-470.
6. [6] R.J. Lutz, R.L. Dedrick, Implications of pharmacokinetic modeling in risk assessment, Environmental Health Perspectives 76 (1987) 97-106.
7. [7] J. Van Ryzin, Quantitative risk assessment, J. Occup. Med. 22 (1980) 321-326.
8. [8] C. Portier, D. Hoel, Low-dose rate extrapolation using the multistage model, Biometrics 39 (1983) 897-906.
9. [9] A. Kopp-Schneider, C.J. Portier, Distinguishing between models of carcinogenesis: the role of clonal expansion, Fund. Appl. Toxicol. 17 (1991) 601-613.
10. [10] A. Kopp-Schneider, Carcinogenesis models for risk assessment, Statist. Meth. Med. Res. 6 (1998) 317-340.
11. [11] P. Armitage, R. Doll, The age distribution of cancer and a multi-stage theory of carcinogenesis, British Journal of Cancer 8 (1954) 1-12.
12. [12] S.H. Moolgavkar, A.G. Knudson, Mutation and cancer: a model for human carcinogenesis, Journal Natl. Cancer Inst. 66 (1981) 1037-1052.
13. [13] A. Whittemore, J.B. Keller, Quantitative theories of carcinogenesis, SIAM Rev. 20 (1978) 1-30.
14. [14] S.H. Moolgavkar, D.J. Venzon, Two-event model for carcinogenesis: incidence curves for childhood and adult tumors, Mathematical Biosciences 47 (1979) 55-77.
15. [15] S.H. Moolgavkar, G. Luebeck, Two-event model for carcinogenesis: biological, mathematical, and statistical considerations, Risk Analysis 10 (1990) 323-334.
16. [16] C. Sherman, C. Portier, : Quantitative analysis of multiple phenotype enzyme - altered foci in rat hepatocarcinogenesis experiments, Carcinogenesis 16 (1995) 2499-2506.
17. [17] C.J. Portier, Statistical properties of a two-stage model of carcinogenesis, Environmental Health Perspectives 76 (1987) 125-131.
18. [18] C.J. Portier, L. Edler, Two-stage models of carcinogenesis, classification of agents, and design of experiments, Fund. Appl. Toxicol. 14 (1990) 444-460.
19. [19] T.W. Thorslund, C.C. Brown, G. Charnley, Biologically motivated cancer risk models, Risk Analysis 7 (1987) 109-119.
20. [20] J.J. Gart, D. Krewski, P.N. Lee, R.E. Tarone, J. Wahrendorf, Statistical Methods in Cancer Research Vol. III. The Design and Analysis of Long-term Animal Experiments, IARC Scientific Publications, Lyon, 1986.
21. [21] M.R. Berger, D. Schmähl, L. Edler, Implications of the carcinogenic hazard of low doses of three hepatocarcinogenic N-nitrosamines, Jpn. J. Cancer Res. 81 (1990) 598-606.
22. [22] H. Druckrey, Quantitative aspects in chemical carcinogenesis, in: R. Truhaut (Ed.), Potential Carcinogenic Hazards from Drugs, UICC Monograph No. 7., Springer, New York, 1967, pp. 60-78.
23. [23] I.F.H. Purchase, T.R. Auton, Thresholds in chemical carcinogenesis, Regulatory Toxicology and Pharmacology 22 (1995) 199-205.
24. [24] D.W. Gaylor, Relationship between the shape of dose-response curves and background tumor rates, Regulatory Toxicology and Pharmacology 16 (1992) 2-9.
25. [25] D.W. Gaylor, Quantitative risk analysis for quantal reproductive and developmental effects, Environmental Health Perspectives 79 (1989) 243-246.
26. [26] D.W. Gaylor, Incidence of development defects at the no observed adverse effect level (NOAEL), Regulatory Toxicology and Pharmacology 15 (1992) 151-160.
27. [27] W. Leisenring, L. Ryan, Statistical properties of the NOAEL, Regulatory Toxicology and Pharmacology 15 (1992) 161-171.
28. [28] L. Edler, C.J. Portier, A. Kopp-Schneider, Zur Existenz von Schwellenwerten: Wissenschaftliche Methode oder statistische Artefakt in der Risikoabschätzung, Zbl. Arbeitsmed. 44 (1994) 16-21.